ZYBERNO
Stock Report
Updated Sep 2, 2026

Aquestive Therapeutics, Inc. (AQST)

Healthcare • NASDAQ

$5.02

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
12.0/100
POOR BUSINESS
Aquestive Therapeutics, Inc. (AQST) scores 12/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-97.5%)
Return on Capital (Capital Efficiency):CRITICAL (-117.7%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Aquestive Therapeutics, Inc. (AQST) stock report — Zyberno Score 12/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, AQST generated -$44.22M in Owner Earnings. Capital was deployed as follows: $479.00K invested in capital expenditures. Reinvestment rate: 0.0%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:5.02
Market Cap:$627.47M

Valuation Multiples (2)

P/S Ratio:11.60x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$584.80M

Price Action & Momentum (3)

Momentum Percentile:68 / 100
% of 52-Week High:66.5%
B. Profitability Assessment

Return Metrics (4)

ROA:-52.4%
Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%

Margin Analysis (3)

Operating Margin Ttm:-97.5%
Net Margin Ttm:-144.6%
Ebitda Margin:-96.6%

TTM Performance (3)

Gross Margin Ttm:67.0%
Operating Margin Ttm:-97.5%
Net Margin Ttm:-144.6%

Yield Metrics (2)

Earnings Yield:-$12.95
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-164.2%
Latest Earnings Filed:2026-08-11

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):2.3%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:7.19x
Quick Ratio:6.74x
Cash Ratio:5.98x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-6.31x
Times Interest Earned:-6.31

Capital Structure (4)

Working Capital:102,016,000.00
Cash And Cash Equivalents:98,490,000.00
Long Term Debt:$55.00M
Net Debt:-$42.67M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $54.09M
Linear Growth: 2.3%
📊 Click to view full AQST Revenue analysis & methodology →
Cost Of Revenue Ttm:$17.83M

Profitability Breakdown (2)

Gross profit TTM: $36.26M
Linear Growth: 3.6%
📊 Click to view full AQST Gross Profit analysis & methodology →
-$52.75M

Bottom Line Performance (3)

-$78.23M
Income Before Tax:-$78.23M
Ebitda Ttm:-52,227,000.00

Operating Expenses (5)

Operating Expenses:106,832,000.00
R And D Expense:15,892,000.00
Sga Expense:73,112,000.00
Income Tax Expense:$0.00
Interest Expense:11,267,000.00

Expense Ratios (3)

R And D To Revenue Percentage:115.0%
Sga To Revenue Percentage:529.1%
Ebitda Margin:-96.6%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$132.10M
Current Assets:$118.49M
Ppe Net:48,221,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:188,690,000.00
Current Liabilities:16,478,000.00
Long Term Debt:$55.00M
Short Term Debt:$820.00K

Equity & Capital (3)

Equity:-$56.59M
Retained Earnings:-$477.92M
Common Stock:250,000,000.00

Working Capital Items (3)

Accounts Receivable:9,326,000.00
Inventory:7,366,000.00
Accounts Payable:8,965,000.00

Special Items (2)

Contract Liabilities:19,937,000.00
Stock Based Compensation:2,895,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$43.84M-$44.32M

Investment Activities (2)

Investing Cash Flow:-$52.00K
Capital Expenditures Ttm:479,000.00

Financing Activities (3)

Financing Cash Flow:$4.42M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$8.00K

Non-Cash Items (1)

Depreciation Amortization Ttm:518,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.65
-$0.65
Earnings Per Share Ttm:-$0.63

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.43
Operating Cash Flow Per Share:-$0.42

Book Value & Capital (2)

Book Value Per Share:-$0.45
Cash Per Share:0.79

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.36x
Working Capital Turnover Ttm:0.53x

Receivables Management (2)

Receivables Turnover Ttm:5.80x
Days Sales Outstanding Ttm:62.94

Inventory Management (2)

Inventory Turnover Ttm:2.42x
Days Inventory Outstanding Ttm:150.81

Payables & Cash Cycle (2)

Days Payable Outstanding:183.54
Cash Conversion Cycle:30.20
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:40.00
Quality Score:25.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$44.22M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):2.3%

Other Growth Rates (1)

Gross Profit Growth Rate (Linear):3.6%
C. Company Profile & Context

Corporate Information (6)

Symbol:AQST
Company Name:Aquestive Therapeutics, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:124.99M
Shares Outstanding Basic:124.99M
Shares Outstanding Diluted:124.99M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-02 00:34:27 UTC
Data Timestamp:2026-09-02T00:34:27.295357
Scroll to Top